Physician profile
Daniel B Miller
NPI 1598704207
$322.16
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $18.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.29 | 2019 | |
| 180 Medical, INC. | $38.66 | 2019 | |
| Boston Scientific Corporation | $37.34 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $34.56 | 2019 | |
| Abbvie INC. | $29.12 | 2019 | |
| Ferring Pharmaceuticals INC. | $28.21 | 2019 | |
| Coloplast Corp | $25.02 | 2019 | |
| Janssen Biotech, INC. | $19.81 | 2019 | |
| Amgen INC. | $18.73 | 2019 | |
| Antares Pharma, INC. | $13.27 | 2019 | |
| Aytu Biopharma, INC. | $11.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,683.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.